Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Infect Genet Evol ; 54: 183-191, 2017 10.
Article in English | MEDLINE | ID: mdl-28688977

ABSTRACT

BACKGROUND: The prevalence of HIV-1 drug resistance among treatment-naïve patients ranges between 8.3% and 15% in Europe and North America. Previous studies showed that subtypes A and B were the most prevalent in the Greek HIV-1 epidemic. Our aim was to estimate the prevalence of resistance among drug naïve patients in Greece and to investigate the levels of transmission networking among those carrying resistant strains. METHODS: HIV-1 sequences were determined from 3428 drug naïve HIV-1 patients, in Greece sampled during 01/01/2003-30/6/2015. Transmission clusters were estimated by means of phylogenetic analysis including as references sequences from patients failing antiretroviral treatment in Greece and sequences sampled globally. RESULTS: The proportion of sequences with SDRMs was 5.98% (n=205). The most prevalent SDRMs were found for NNRTIs (3.76%), followed by N(t)RTIs (2.28%) and PIs (1.02%). The resistance prevalence was 22.2% based on all mutations associated with resistance estimated using the HIVdb resistance interpretation algorithm. Resistance to NNRTIs was the most common (16.9%) followed by PIs (4.9%) and N(t)RTIs (2.8%). The most frequently observed NNRTI resistant mutations were E138A (7.7%), E138Q (4.0%), K103N (2.3%) and V179D (1.3%). The majority of subtype A sequences (89.7%; 245 out of 273) with the dominant NNRTI resistance mutations (E138A, K103N, E138Q, V179D) were found to belong to monophyletic clusters suggesting regional dispersal. For subtype B, 68.1% (139 out of 204) of resistant strains (E138A, K103N, E138Q V179D) belonged to clusters. For N(t)RTI-resistance, evidence for regional dispersal was found for 27.3% and 21.6% of subtype A and B sequences, respectively. CONCLUSIONS: The TDR rate based on the prevalence of SDRM is lower than the average rate in Europe. However, the prevalence of NNRTI resistance estimated using the HIVdb approach, is high in Greece and it is mostly due to onward transmissions among drug-naïve patients.


Subject(s)
Drug Resistance, Viral , HIV Infections/epidemiology , HIV Infections/virology , HIV-1/drug effects , Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , Female , Genotype , Greece/epidemiology , HIV Infections/drug therapy , HIV Infections/transmission , HIV-1/classification , HIV-1/genetics , Humans , Male , Mutation , Phylogeny , Prevalence
2.
Chem Commun (Camb) ; 52(92): 13515, 2016 11 10.
Article in English | MEDLINE | ID: mdl-27805204

ABSTRACT

Correction for 'Identification of the key structural elements of a dihydropyrimidinone core driving toward more potent Hsp90 C-terminal inhibitors' by S. Teracciano et al., Chem. Commun., 2016, 52, 12857-12860.

3.
Chem Commun (Camb) ; 52(87): 12857-12860, 2016 10 25.
Article in English | MEDLINE | ID: mdl-27731433

ABSTRACT

Hsp90 C-terminal modulation represents an attractive strategy for the development of potent and safer antitumor compounds. Continuing our investigation on DHPM type inhibitors here we report a new set of potent C-terminal ligands which allowed us to identify the key structural features crucial for the biological activity.

4.
Sci Rep ; 4: 3959, 2014 Mar 12.
Article in English | MEDLINE | ID: mdl-24618651

ABSTRACT

The present work reports the analysis of a possible relationship due to stress transfer between the two earthquakes that hit the province of Van, Eastern Turkey, on October 23, 2011 (Mw = 7.2) and on November 9, 2011 (Mw = 5.6). The surface displacement field of the mainshock has been obtained through a combined data set made up of differential interferograms from COSMO-SkyMed and ENVISAT satellites, integrated with continuous GPS recordings from the Turkish TUSAGA-AKTIF network. This allowed us to retrieve the geometry and the slip distribution of the seismic source and to compute the Coulomb Failure Function (CFF) variation on the aftershock plane, in order to assess a possible causal relationship between the two events. Our results show that the November 9 earthquake could have been triggered by the October 23 shock, with transferred stress values largely exceeding 1 bar.

6.
J Chemother ; 24(1): 38-47, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22546723

ABSTRACT

OBJECTIVE: To evaluate the long-term effects of different boosted protease inhibitors (bPIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based antiretroviral regimens on lipid levels in HIV seropositive individuals who have not received lipid-lowering agents. METHODS: Data consisted of 595 patients participating in the population-based Athens Multicenter Cohort Study who were consistently followed up during 1996-2008. RESULTS: In naïve patients, lipid parameters increased sharply during the first 3 months of antiretroviral therapy and reached a plateau level approximately 6-9 months after therapy initiation. The plateau levels remained almost stable for up to 3.5 years. In general, bPIs exerted a more pronounced effect compared to NNRTIs. CONCLUSIONS: The administration of PI- or NNRTI-based regimens especially in naïve but also in unboosted PI experienced patients provoked a sharp increase in lipid levels that remained stable in higher levels for more than 3 years.


Subject(s)
Antiretroviral Therapy, Highly Active , HIV Infections/blood , HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , HIV/drug effects , Lipids/analysis , Reverse Transcriptase Inhibitors/therapeutic use , Adolescent , Adult , Cohort Studies , Female , Greece/epidemiology , HIV Infections/epidemiology , Humans , Male , Middle Aged , Young Adult
7.
Int J Immunopathol Pharmacol ; 25(1): 247-58, 2012.
Article in English | MEDLINE | ID: mdl-22507337

ABSTRACT

Human Immunodeficiency Virus (HIV)-infected patients are at increased risk for cardiovascular diseases partly due to chronic inflammation. Some antiretroviral drugs and Highly Active Anti-Retroviral Therapy (HAART) regimens seem to be related and amplify this increased risk, especially the ones containing abacavir. Platelet-Activating-Factor (PAF) is a potent inflammatory mediator that is implicated in both cardiovascular diseases and HIV-related manifestations. Our objective is to study the in vivo effect of the abacavir/lamivudine/efavirenz first-line HAART regimen on PAF metabolism in HIV-infected patients. The specific activities of PAF basic biosynthetic enzymes in leukocytes and platelets, PAF-cholinephosphotransferase (PAF-CPT) and lyso-PAF-acetyltransferase (Lyso-PAF-AT), but also those of PAF-basic catabolic enzymes, PAF acetylhydrolase (PAF-AH) in leukocytes and platelets and Lipoprotein-associated-Phospholipase-A2 (LpPLA2) in plasma, were measured in blood samples of 10 asymptomatic naïve male HIV-infected patients just before and after 1, 3 and 6 months of treatment. CD4 cell counts, viral load and several biochemical markers were also measured in the same blood samples of these patients. The repeated ANOVA measures and the Pearson r criterion were used for studying statistical differences and correlations - partial correlations respectively. Even though viral load was decreased and CD4 cell counts were beneficially increased after treatment with the abacavir/lamivudine/efavirenz regimen, the main enzyme of the remodelling PAF-synthesis that is implicated in pro-atherogenic inflammatory procedures, Lyso-PAF-AT activity, was increased at 3 months of treatment in both leukocytes and platelets, while the main enzyme of PAF-degradation, PAF-AH, was increased as a response only in leukocytes at the 3rd month. Although the abacavir/lamivudine/efavirenz HAART regimen exhibits very efficient antiretroviral activities, on the other hand it induces an in vivo transient increase in the inflammation-related remodeling PAF-biosynthetic pathway. This finding supports the hypothesis of inflammation-mediated increased cardiovascular risk in HIV-infected patients during the first months of abacavir-containing HAART.


Subject(s)
Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active , HIV Infections/drug therapy , Platelet Activating Factor/metabolism , Adult , Alkynes , Benzoxazines/administration & dosage , CD4 Lymphocyte Count , Cyclopropanes , Dideoxynucleosides/administration & dosage , Drug Combinations , Drug Therapy, Combination , HIV Infections/metabolism , Humans , Lamivudine/administration & dosage , Male , Middle Aged , Viral Load
8.
Vox Sang ; 92(1): 8-14, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17181585

ABSTRACT

BACKGROUND AND OBJECTIVES: The Procleix Ultrio human immunodeficiency virus type 1 (HIV-1)/hepatitis C virus (HCV)/hepatitis B virus (HBV) (Ultrio) assay simultaneously detects HIV-1 RNA, HCV RNA and HBV DNA in individual blood donations. The main objective of the study was to assess the analytical and clinical sensitivity of the multiplex and discriminatory probe assays in samples with a low viral load. MATERIAL AND METHODS: The VQC HIV RNA genotype B, HCV RNA genotype 1 and HBV DNA genotype A standard dilutions were tested in 26 repeats. The probability of detection by Ultrio was compared with previously obtained data of the Procleix Duplex HIV-1/HCV assay on the same reference panels. A selection of 121 anti-HIV-1, 138 anti-HCV and 190 HBsAg positive samples from patients receiving antiviral therapy were tested. The majority of patient samples had a viral load below the detection limit of the diagnostic nucleic acid test assays, which made them suitable to evaluate the performance of the multiplex and discriminatory assays on yield cases with a similar low viral load. RESULTS: The 95% and 50% detection end-points of the Ultrio assay along with the corresponding 95% confidence intervals are 53.7 (32.9-117.2) and 8.6 (6.2-12.1) geq/ml for HIV-1 RNA, 30.3 (19.0-62.4) and 5.2 (3.7-7.2) geq/ml for HCV RNA and 393.7 (147.9-6978) and 54.5 (22.4-143.8) geq/ml for HBV DNA. The analytical sensitivity of Ultrio expressed as a potency factor relative to previously obtained Duplex results on the same HIV-1 RNA and HCV-RNA standard dilutions was 1.09 (0.20-6.10) and 1.11 (0.21-5.89), respectively. The assay detected all 22 HIV-1 infected patients with viral load > 50 copies/ml, and 41 of 99 patients (41%) with viral load < 50 copies/ml, of which 23 (56%) were detected by the discriminatory assay. All 47 patients with HCV RNA load > 521 IU/ml and 10/91 polymerase chain reaction-negative patients with viral load < 50 IU/ml tested positive in Ultrio assay of which five were missed in the discriminatory test. The assay detected 53/55 HBV infected patients (96%) with viral load > 250 copies/ml and 108/135 patients (80%) with viral load < 250 copies/ml of which 17 (16%) were missed by the discriminatory test. CONCLUSIONS: The new Procleix Ultrio assay is as sensitive as the Procleix Duplex assay for HIV-1 and HCV detection meeting the requirements of universal guidelines. The ability of the assay to detect HBV DNA in low viral load samples could be useful for screening blood. Inevitable negative results of discriminatory probe assays caused by stochastic sample variation will reduce the chance of recognizing low viraemic blood donors detected by individual donation nucleic acid test.


Subject(s)
Blood Donors , HIV Infections/diagnosis , Hepatitis B/diagnosis , Hepatitis C/diagnosis , Serologic Tests/methods , Viral Load , HIV Infections/blood , HIV-1/genetics , HIV-1/isolation & purification , Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepatitis B/blood , Hepatitis B virus/genetics , Hepatitis B virus/isolation & purification , Hepatitis C/blood , Humans , Nucleic Acid Amplification Techniques/methods , Sensitivity and Specificity
9.
Virus Res ; 112(1-2): 115-22, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16022906

ABSTRACT

The prevalence of HIV-1 drug resistance mutations in naïve patients has been previously shown to differ greatly with the geographic origin. The purpose of this study was to prospectively estimate the prevalence of HIV-1 drug resistance in Greece by analyzing a representative sample of newly HIV-1 diagnosed patients, as part of the SPREAD collaborative study. Protease (PR) and partial reverse transcriptase (RT) sequences were determined from 101 newly diagnosed HIV-1 patients, in Greece, during the period September 2002--August 2003, representing one-third of the total newly diagnosed HIV-1 patients in the same time period. The prevalence of HIV-1 drug resistance was estimated according to the IAS-USA mutation table taking into account all mutations in RT and only major mutations in PR region. The overall prevalence of resistance was 9% [95% confidence interval (CI): 4.2--16.2%]. The prevalence of mutations associated with resistance to NRTIs was 5% (95% CI: 1.6--11.2%), for NNRTIs was 4% (95% CI: 1.1--9.8%), while no major resistance mutations were found in PR. No multi-class resistance was detected in the study population. The prevalence of resistant mutations in the recent seroconverters was 22%. For two individuals, there was clear evidence for transmitted resistance based on epidemiological information for a known source of HIV-1 transmission. The prevalence of the HIV-1 non-B subtypes and recombinants was 52%.


Subject(s)
Drug Resistance, Viral/genetics , HIV Infections/epidemiology , HIV Infections/virology , HIV-1/drug effects , Mutation , Adult , Anti-HIV Agents/pharmacology , Female , Greece/epidemiology , HIV Infections/diagnosis , HIV Protease/genetics , HIV Protease Inhibitors/pharmacology , HIV Reverse Transcriptase/genetics , HIV-1/classification , HIV-1/genetics , Humans , Male , Microbial Sensitivity Tests/methods , Middle Aged , Prevalence , Reverse Transcriptase Inhibitors/pharmacology , Sequence Analysis, DNA
10.
Virus Res ; 85(1): 109-15, 2002 Apr 23.
Article in English | MEDLINE | ID: mdl-11955643

ABSTRACT

The widespread use of antiviral drugs against HIV has increased the prevalence of HIV-1 resistant strains among naïve individuals due to transmission of resistant strains. The purpose of this study was to investigate the presence of HIV-1 strains harboring resistance mutations in naïve patients in Greece. Blood samples were collected from 25 individuals. The DNA sequence of protease and partial reverse transcriptase regions (codons 41-223) were obtained by direct sequencing. Our results showed the absence of any primary resistance mutations in the study population. However, we were able to identify high prevalence of sequence polymorphisms at positions in reverse transcriptase region associated mainly with resistance to NNRTIs. Moreover, in protease region several secondary mutations were detected, suggesting the higher genetic variability of this region. The clinical significance of the polymorphisms associated with reduced susceptibility to NNRTIs remains to be clarified.


Subject(s)
Anti-HIV Agents/therapeutic use , Drug Resistance, Viral/genetics , HIV Infections/virology , HIV-1/drug effects , HIV-1/genetics , Mutation , Amino Acid Sequence , Gene Frequency , Genotype , Greece , HIV Infections/drug therapy , HIV Protease/genetics , HIV Reverse Transcriptase/genetics , Humans , Molecular Sequence Data , Polymorphism, Genetic , Reverse Transcriptase Inhibitors/pharmacology
11.
Arch Androl ; 12(2-3): 235-42, 1984.
Article in English | MEDLINE | ID: mdl-6439137

ABSTRACT

Primary hypogonadism has been commonly reported among uremic men on hemodialysis, characterized by low testosterone levels, increased luteinizing hormone and sometimes follicle-stimulating hormone levels. Little is known about the influence of hyperprolactinemia and age on this hypogonadism. In 149 hemodialysis patients and in 60 healthy subjects the serum levels of testosterone (T), gonadotropins (LH and FSH) and prolactin (PRL) were assessed through radioimmunoassay. Mean +/- SD hormone levels were: T 274 +/- 125 ng/100 ml, lower than controls; LH 44.7 +/- 46.1 mlU/ml and FSH 17.6 +/- 18.4 mIU/ml, both higher than controls. PRL 31.3 +/- 49.4 ng/ml, higher than controls. A positive correlation between LH and FSH, a negative correlation between PRL and both T and LH was found. Moreover T and FSH were correlated with age only in the normoprolactinemic patients. These data suggest: a common damaging mechanism by uremia on both interstitial and tubular structures of the testis; a central antigonadal influence of hyperprolactinemia even if a direct action on the testis cannot be excluded; a worsening action of age on the gonadal function of these patients.


Subject(s)
Aging , Hypogonadism/etiology , Prolactin/blood , Renal Dialysis , Uremia/complications , Adult , Aged , Follicle Stimulating Hormone/blood , Humans , Hypogonadism/blood , Luteinizing Hormone/blood , Male , Middle Aged , Testosterone/blood , Uremia/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...